Table 6.
Overview of LAMB formulations introduced in the market or under development*.
| Company | Country | Brand name | Year of marketing approval in the country of origin | Storage conditions | Presentation (special warnings before use) |
|---|---|---|---|---|---|
| Gilead | USA | AmBisome™ | 1997 | Below 25°C | Lyophilized (reconstitution, filtration and dilution before use) |
| Lifecare | India | Fungisome™ | 2003 | 2 – 8°C | Liquid (sonication 45 min before use) |
| Cipla | India | Phosome™ | 2008 | 2 – 8°C | Lyophilized (reconstitution, filtration and dilution before use) |
| Sun Pharma | India | Lambin™ | 2009 | 2 – 8°C | Lyophilized (reconstitution, filtration and dilution before use) |
| Lyka Labs | India | Lipholyn™ | 2010 | 2 – 8°C | Lyophilized (reconstitution, filtration and dilution before use) |
| Celon Labs | India | Under development | 2 – 8°C | Lyophilized (reconstitution, filtration and dilution before use) | |
| Laboratorios Richmond | Argentina | Withdrawn, under further development (Anfogen) | Lyophilized (reconstitution, filtration and dilution before use) | ||
| Genex Pharma | India | Under development | |||
| Claris Lifescience | India | Under development | |||
| TTY Pharma | Taiwan | Under development | |||
*This table is not exhaustive as some producers from India and Taiwan have chosen not to disclose information about their products under development.
LAMB: Liposomal amphotericin B.